Atomo Diagnostics Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Key Metrics
PE ratio
-
PB ratio
4.67
Dividend yield
-
Beta
1.19
Market cap
$34.03M
Enterprise value
$30.99M
Company profile
| Industry / Sector | Medical Devices / Healthcare |
|---|---|
| Website | https://atomodiagnostics.com |
| Mailing address | 3-5 George Street Level 1 Leichhardt NSW 2040 Australia |
| Phone / Fax | 61 2 9099 4750 / |
Dividends
More: Atomo Diagnostics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Atomo Diagnostics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AT1 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Atomo Diagnostics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. John Michael Kelly | Founder, CEO & MD | ||
| Ms. Chandra Sukumar | Chief Operating Officer | ||
| Suzy Elhlou | Finance Manager | ||
| Mr. Mathew Leslie Watkins C.A. | Company Secretary |
Profitability and management effectiveness
Profit margin
-131.08%
Operating margin
-166.84%
Return on assets
-35.32%
Return on equity
-58.27%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Atomo Diagnostics is 34.03M and its enterprise value is 30.99M. The enterprise value to revenue ratio of AT1 is 8.17. The enterprise value to EBITDA ratio of AT1 is -6.60.
The AT1's stocks Beta value is 1.19 making it 19% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Atomo Diagnostics (AT1)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Polynovo (PNV)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Atomo Diagnostics (ASX:AT1) Frequently Asked Questions
1. What is Atomo Diagnostics's Stock Symbol?
Atomo Diagnostics trades on ASX under the ticker symbol "AT1".
2. What is Atomo Diagnostics's stock price today?
One share of AT1 stock can currently be purchased for approximately $0.042.
3. How can I contact Atomo Diagnostics?
Atomo Diagnostics's mailing address is 3-5 George Street Level 1 Leichhardt NSW 2040 Australia. The company can be reached via phone at 61 2 9099 4750.
4. What is Atomo Diagnostics's official website?
The official website of Atomo Diagnostics is https://atomodiagnostics.com.